| Estimated Vaccination Coverage^ with Individual Vaccines and Vaccination Series Among Children 19-35 Months of Age by Race/Ethnicity* -- US, National Immunization Survey, Q1/2009-Q4/2009 |
4+DTaP | 3+Polio§ | 1+MMRll | 3+HibΆ | **Hib by brand | 3+HepB | HepB Birth DoseΆΆ | 1+Var | 3+PCV§§ | 4+PCVllll | HepA*** | Rotavirus | 4:3:1 | 4:3:1:0:3:1:4 | 4:3:1:4:3:1:4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| US National₯ | 83.9±1.0 | 92.8±0.7 | 90.0±0.8 | 83.6±1.0 | 54.8±1.4 | 92.4±0.7 | 60.8±1.3 | 89.6±0.8 | 92.6±0.7 | 80.4±1.1 | 46.6±1.4 | 43.9±1.4 | 81.5±1.1 | 70.5±1.2 | 44.3±1.4 |
| White only, non-Hispanic | 85.8±1.1 | 93.3±0.8 | 90.8±0.9 | 82.9±1.2 | 55.3±1.6 | 92.3±0.9 | 58.8±1.6 | 89.2±1.0 | 93.2±0.8 | 83.4±1.2 | 42.6±1.6 | 46.4±1.6 | 83.5±1.2 | 72.4±1.4 | 45.2±1.6 |
| Black only, non-Hispanic | 78.6±3.1 | 90.9±2.3 | 88.2±2.7 | 80.4±3.1 | 51.2±3.7 | 91.6±2.2 | 61.7±3.7 | 88.2±2.7 | 91.5±2.2 | 73.2±3.4 | 41.3±3.7 | 38.0±3.6 | 76.6±3.3 | 64.3±3.6 | 39.6±3.6 |
| Hispanic | 82.9±2.5 | 92.5±1.8 | 89.3±2.0 | 86.4±2.2 | 55.4±3.3 | 92.6±1.7 | 64.7±3.1 | 90.7±1.9 | 92.7±1.7 | 80.6±2.5 | 49.3±3.3 | 43.7±3.2 | 80.4±2.6 | 72.0±2.9 | 45.9±3.3 |
| American Indian or Alaska Native only, non-Hispanic | 82.1±8.1 | 92.2±5.5 | 94.9±3.1 | 88.3±5.9 | NA | 92.5±5.2 | NA | 89.2±6.3 | 94.4±4.6 | 76.2±9.2 | 33.2±9.8 | NA | 80.6±8.3 | NA | NA |
| Asian only, non-Hispanic | 86.6±5.5 | 94.0±3.4 | 90.7±4.3 | 81.4±6.4 | 54.6±8.8 | 93.1±3.2 | 53.3±9.2 | 89.5±5.3 | 88.5±5.0 | 72.5±9.5 | 50.9±9.1 | 41.7±8.6 | 84.0±5.9 | 62.5±9.1 | 38.6±7.9 |
| Native Hawaiian or Other Pacific Islander only, non-Hispanic | 93.1±4.7 | 97.3±2.6 | 96.9±3.2 | 88.3±5.9 | NA | 96.2±3.6 | NA | 97.5±2.5 | 96.5±5.6 | NA | 61.4±18.5 | NA | 92.4±5.0 | NA | NA |
| Multiple Race, non-Hispanic | 81.8±4.1 | 92.8±3.0 | 88.5±3.8 | 83.7±4.0 | 53.7±5.9 | 93.3±2.6 | 60.7±5.9 | 90.6±3.1 | 91.1±3.0 | 73.1±5.7 | 47.8±5.9 | 38.4±5.6 | 78.4±4.6 | 63.4±5.8 | 40.7±5.6 |
| ^ Estimate=NA (Not Available) if the unweighted sample size for the denominator was <30 or (CI half width)/Estimate > 0.6. | ||||||||||||
| Estimates presented as point estimate (%) ± 95% Confidence Interval. | ||||||||||||
| * Self-reported by respondent. Individual racial groups do not include Hispanic children. Children of Hispanic ethnicity may be of any race. | ||||||||||||
| Children in the Q1/2009-Q4/2009 National Immunization Survey were born between January 2006 and July 2008. | ||||||||||||
| ₯ US National estimates include the 50 States plus DC, and exclude the Virgin Islands. | ||||||||||||
| 4 or more doses of any diphtheria and tetanus toxoids and pertussis vaccines including diphtheria and tetanus toxoids, and any acellular pertussis vaccine (DTaP/DTP/DT). | ||||||||||||
| § 3 or more doses of any poliovirus vaccine. | ||||||||||||
| ll 1 or more doses of measles-mumps-rubella vaccine. | ||||||||||||
| Ά 3 or more doses of Haemophilus influenzae type b (Hib) vaccine of any type. | ||||||||||||
| **≥3 or ≥4 doses of Hib vaccine depending on product type received. It includes the primary series plus the booster dose. | ||||||||||||
| 3 or more doses of hepatitis B vaccine. | ||||||||||||
| 1 or more doses of varicella at or after child's first birthday, unadjusted for history of varicella illness. | ||||||||||||
| §§ 3 or more doses of pneumococcal conjugate vaccine (PCV). | ||||||||||||
| llll 4 or more doses of PCV. | ||||||||||||
| ΆΆ Hepatitis B vaccine administered between birth and age 3 days. | ||||||||||||
| *** Hepatitis A coverage with ≥2 doses of vaccine. | ||||||||||||
| Rotavirus vaccine includes ≥2 or ≥3 doses depending on product type received. | ||||||||||||
| 4 or more doses of DTaP vaccine, 3 or mored doses of poliovirus vaccine, and 1 or more doses of measles, mumps and rubella vaccine. | ||||||||||||
| 4:3:1 plus 3 or more doses HepB vaccine, 1 or more doses of varicella vaccine and 4 or more doses of PCV. Hib vaccine is excluded. | ||||||||||||
| 4:3:1 plus Hib vaccine depending on product type (>3 or >4 doses), 3 or more doses of HepB, 1 or more doses of varicella, and 4 or more doses of PCV. | ||||||||||||
| tab30_race_nat | ||||||||||